Recent advances in the treatment of systemic mycotic infections.
Serious therapeutic problems are posed by the increasing incidence of invasive fungal infections in transplant recipients as well as in patients with compromised immune defenses, prosthetic devices and grafts and several other predisposing factors. A number of new approaches, including combination drug treatment and the development of newer agents, may justify increased optimism in the management of these infections.
D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000818:Animals; D000935:Antifungal Agents / Q000627:therapeutic use*; D003453:Cryptococcosis / Q000188:drug therapy; D004359:Drug Therapy, Combination; D005437:Flucytosine / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007109:Immunity; D016030:Kidney Transplantation; D008825:Miconazole / Q000627:therapeutic use; D009181:Mycoses / Q000188:drug therapy* / Q000517:prevention & control
D000935:Antifungal Agents; D008825:Miconazole; D000666:Amphotericin B; D005437:Flucytosine